Cigna Group (CI) — SEC Filings

Latest SEC filings for Cigna Group (CI), explained in plain English.

Sentiment Overview: 1 bullish, 48 neutral

Recent Filings (49)

• 8-K Filing — 8-K · 2025-11-18T00:00:00.000Z [neutral]
• Cigna Group Files 8-K on Financials — 8-K · 2025-10-30T00:00:00.000Z [neutral] Risk: low
  The Cigna Group filed an 8-K on October 30, 2025, to report on its results of operations and financial condition. The filing includes financial statements and e
• Cigna's Q3 Earnings Soar on Strong Pharmacy Growth, Medicare Divestiture — 10-Q · 2025-10-30T00:00:00.000Z [bullish] Risk: medium
  Cigna Group reported robust financial performance for the three and nine months ended September 30, 2025. Total revenues for the three months increased to $69.7
• Cigna Group Reports Director Changes and Compensation Updates — 8-K · 2025-10-20T00:00:00.000Z [neutral] Risk: low
  On October 15, 2025, The Cigna Group reported changes in its board of directors and executive compensation arrangements. Specifically, the company announced the
• Cigna Group Files 8-K: Material Agreement and Financial Updates — 8-K · 2025-09-04T00:00:00.000Z [neutral] Risk: medium
  On September 4, 2025, The Cigna Group entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or
• Cigna Group Files 8-K Report — 8-K · 2025-09-02T00:00:00.000Z [neutral] Risk: low
  On September 2, 2025, The Cigna Group filed an 8-K report. The filing indicates that the company is incorporated in Delaware and its principal executive offices
• Cigna Group Files 8-K on Operations and Financials — 8-K · 2025-07-31T00:00:00.000Z [neutral] Risk: low
  On July 31, 2025, The Cigna Group filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as fin
• 10-Q Filing — 10-Q · 2025-07-31T00:00:00.000Z [neutral]
• Cigna Group Files 8-K/A Amendment — 8-K/A · 2025-07-28T00:00:00.000Z [neutral] Risk: low
  The Cigna Group filed an 8-K/A amendment on July 28, 2025, related to events occurring on May 30, 2025. The filing pertains to the departure of directors or cer
• Cigna Group Reports Board Changes and Executive Compensation Updates — 8-K · 2025-06-02T00:00:00.000Z [neutral] Risk: low
  On May 30, 2025, The Cigna Group filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing includes in
• Cigna Group Files 8-K for Regulation FD Disclosure — 8-K · 2025-05-20T00:00:00.000Z [neutral] Risk: low
  On May 20, 2025, The Cigna Group filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure. No specific financial transac
• Cigna Group Files 8-K on Financials — 8-K · 2025-05-02T00:00:00.000Z [neutral] Risk: low
  The Cigna Group filed an 8-K on May 2, 2025, reporting on its financial condition and results of operations. The filing includes financial statements and exhibi
• Cigna Group Files Q1 2025 10-Q — 10-Q · 2025-05-02T00:00:00.000Z [neutral] Risk: low
  Cigna Group filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025.
• Cigna Group Files 8-K with Material Agreements and Officer Changes — 8-K · 2025-04-28T00:00:00.000Z [neutral] Risk: medium
  On April 22, 2025, The Cigna Group entered into a material definitive agreement and also terminated a material definitive agreement. The company also created a
• Cigna Group Announces Board Changes and Executive Compensation Updates — 8-K · 2025-04-18T00:00:00.000Z [neutral] Risk: low
  On April 15, 2025, The Cigna Group reported changes in its board of directors and executive compensation arrangements. Specifically, the company announced the d
• Cigna Group Files 8-K with Financials and Exhibits — 8-K · 2025-03-19T00:00:00.000Z [neutral] Risk: low
  On March 19, 2025, The Cigna Group filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or tra
• Cigna Group Files Proxy Materials — DEFA14A · 2025-03-14T00:00:00.000Z [neutral] Risk: low
  The Cigna Group filed a Definitive Additional Materials proxy statement (DEFA14A) on March 14, 2025. This filing relates to the company's proxy materials, which
• Cigna Group Files 2025 Proxy Statement — DEF 14A · 2025-03-14T00:00:00.000Z [neutral] Risk: low
  The Cigna Group filed its DEF 14A on March 14, 2025, for the fiscal year ending December 31, 2024. This filing details executive compensation and board member i
• Cigna Group Announces Board and Executive Compensation Changes — 8-K · 2025-03-13T00:00:00.000Z [neutral] Risk: low
  On March 10, 2025, The Cigna Group filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the filing announce
• Cigna Group Files 8-K for Regulation FD Disclosure — 8-K · 2025-03-03T00:00:00.000Z [neutral] Risk: low
  On March 3, 2025, The Cigna Group filed an 8-K report. The filing primarily concerns Regulation FD disclosures, indicating that the company is providing informa
• Cigna Group Files 2024 10-K Report — 10-K · 2025-02-27T00:00:00.000Z [neutral] Risk: medium
  The Cigna Group filed its 2024 10-K report on February 27, 2025, detailing its financial performance for the fiscal year ending December 31, 2024. The company,
• Cigna Group Files 8-K on Financials — 8-K · 2025-01-30T00:00:00.000Z [neutral] Risk: low
  On January 30, 2025, The Cigna Group filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as
• SC 13G Filing — SC 13G · 2024-11-12T00:00:00.000Z [neutral]
• Cigna Group Files 8-K on Financials — 8-K · 2024-10-31T00:00:00.000Z [neutral] Risk: low
  On October 31, 2024, The Cigna Group filed an 8-K report detailing results of operations and financial condition. The filing includes financial statements and e
• Cigna Group Files Q3 2024 10-Q — 10-Q · 2024-10-31T00:00:00.000Z [neutral] Risk: low
  Cigna Group filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter of 2
• Cigna Group Affirms 2024 Earnings Guidance — 8-K · 2024-09-03T00:00:00.000Z [neutral] Risk: low
  On September 3, 2024, The Cigna Group filed an 8-K to affirm its earnings guidance for the full year 2024. The company expects to achieve adjusted earnings per
• Cigna Group Files Q2 2024 10-Q Report — 10-Q · 2024-08-01T00:00:00.000Z [neutral] Risk: medium
  Cigna Group filed its 10-Q for the period ending June 30, 2024. The filing covers financial performance and operational details for the second quarter and the f
• Cigna Group Files 8-K with Financial Updates — 8-K · 2024-08-01T00:00:00.000Z [neutral] Risk: low
  On August 1, 2024, The Cigna Group filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits, pr
• Cigna Group Reports Officer and Director Changes — 8-K · 2024-06-20T00:00:00.000Z [neutral] Risk: medium
  The Cigna Group filed an 8-K on June 20, 2024, reporting changes effective June 14, 2024. These changes include the departure of directors or certain officers,
• Cigna Group Affirms 2024 Financial Guidance — 8-K · 2024-06-06T00:00:00.000Z [neutral] Risk: low
  On June 6, 2024, The Cigna Group filed an 8-K to affirm its previously issued financial guidance for the full year 2024. The company reiterated its expectation
• Cigna Group Files Q1 2024 10-Q — 10-Q · 2024-05-02T00:00:00.000Z [neutral] Risk: low
  Cigna Group reported its first quarter 2024 results, ending March 31, 2024. The company's filing provides financial data for the period, including details on it
• Cigna Group Files 8-K for Financial Results — 8-K · 2024-05-02T00:00:00.000Z [neutral] Risk: low
  On May 2, 2024, The Cigna Group filed an 8-K report detailing its financial results. The company, formerly known as Cigna Corp and Halfmoon Parent, Inc., is inc
• Cigna Group Enters Material Definitive Agreement — 8-K · 2024-04-26T00:00:00.000Z [neutral] Risk: medium
  On April 25, 2024, The Cigna Group entered into a material definitive agreement related to a direct financial obligation. The company, formerly known as Cigna C
• Cigna Group Files Proxy Statement Addendum — DEFA14A · 2024-04-12T00:00:00.000Z [neutral] Risk: low
  The Cigna Group filed a Definitive Additional Materials proxy statement on April 12, 2024. This filing is related to the company's proxy materials, which are us
• Cigna Group Files Proxy Materials — DEFA14A · 2024-04-05T00:00:00.000Z [neutral] Risk: low
  The Cigna Group filed a Definitive Additional Materials proxy statement (DEFA14A) on April 5, 2024. This filing is related to the company's proxy materials and
• Cigna Group Files Proxy Materials Amendment — DEFA14A · 2024-03-15T00:00:00.000Z [neutral] Risk: low
  The Cigna Group filed a Definitive Additional Materials proxy statement on March 15, 2024. This filing is an amendment to previous proxy materials and does not
• Cigna Group Files Annual DEF 14A with Executive Compensation Details — DEF 14A · 2024-03-15T00:00:00.000Z [neutral] Risk: medium
  The Cigna Group filed its DEF 14A on March 15, 2024, for the fiscal year ending December 31, 2023. This filing provides detailed information regarding the compa
• Cigna Group Files 8-K Report — 8-K · 2024-03-07T00:00:00.000Z [neutral] Risk: low
  On March 7, 2024, The Cigna Group filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific
• Cigna Group Files 2023 10-K, Details Healthcare Operations — 10-K · 2024-02-29T00:00:00.000Z [neutral] Risk: medium
  Cigna Group filed its 10-K on February 29, 2024, for the fiscal year ending December 31, 2023. The filing details the company's financial performance and operat
• Cigna Group Files 8-K for Other Events and Exhibits — 8-K · 2024-02-15T00:00:00.000Z [neutral] Risk: medium
  The Cigna Group filed an 8-K on February 15, 2024, reporting an event that occurred on February 14, 2024. The filing indicates 'Other Events' and 'Financial Sta
• Cigna Reports Material Agreement & New Financial Obligation — 8-K · 2024-02-13T00:00:00.000Z [neutral] Risk: medium
  The Cigna Group filed an 8-K on February 13, 2024, reporting the entry into a Material Definitive Agreement and the creation of a Direct Financial Obligation. T
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• FMR LLC Cuts Cigna Stake to 4.962%, Below 5% Threshold — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  FMR LLC, a major investment firm, has updated its ownership in Cigna Group, reporting beneficial ownership of 14,521,157 shares of common stock, representing 4.
• Cigna Files 8-K on Feb 7 for Feb 5 Event; Details Pending — 8-K · 2024-02-07T00:00:00.000Z [neutral]
  The Cigna Group filed an 8-K on February 7, 2024, reporting an event that occurred on February 5, 2024. This filing is categorized under "Other Events" and "Fin
• Cigna Files 8-K on Financial Condition & Operations — 8-K · 2024-02-02T00:00:00.000Z [neutral]
  The Cigna Group filed an 8-K on February 2, 2024, to report on its results of operations and financial condition. This filing, under SEC File Number 001-38769,
• Cigna Files 8-K for Administrative Update, No New Financials — 8-K · 2024-01-31T00:00:00.000Z [neutral]
  The Cigna Group filed an 8-K on January 31, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits.' This filing primarily serves to update adm
• BlackRock Amends Cigna Stake, Signals Continued Confidence — SC 13G/A · 2024-01-25T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, reporting its ownership of Cigna Group (formerly Cigna Corporation) common stock as of December 31
• Cigna 8-K: Officer Compensation Arrangements Updated Jan 16 — 8-K · 2024-01-22T00:00:00.000Z [neutral]
  The Cigna Group filed an 8-K on January 22, 2024, reporting an event that occurred on January 16, 2024, related to changes in compensatory arrangements for cert
• Cigna Files 8-K on Executive Compensatory Arrangements — 8-K · 2024-01-17T00:00:00.000Z [neutral]
  The Cigna Group filed an 8-K on January 17, 2024, reporting an event that occurred on January 16, 2024, related to changes in its executive compensation arrange